A patent recently issued to San Diego-based OncoSec Medical Inc. offers the company potential to expand its commercial opportunities for minimally invasive and surgical procedures to treat solid tumors in China.
The patent recently issued by the State Intellectual Property Office of the People’s Republic of China is for the Method and Device for Treating Microscopic Residual Tumors Remaining in Tissues Following Surgical Resection.
OncoSec Medical is developing advanced-stage ImmunoPulse and NeoPulse technologies. These investigational therapies involve injecting a tumor with an anti-cancer agent, followed by electroporation to open up the cell membrane, which helps increase the uptake of the agent. OncoSec says the process has been shown to selectively kill cancer cells that may exist in the neighboring tissue, which may result in a reduced rate of recurrence and has the potential to complement standard-of-care surgical procedures.
Punit Dhillon, OncoSec’s president and CEO, said the Chinese authorities have given the company patent approval for its claims regarding the OncoSec Medical System electroporation device as well as the method of use.
“These are broad claims, wherein OncoSec now has the ability to deliver various therapeutic agents through its electroporation device, including bleomycin and DNA IL-12, as well as to treat tumors with these agents following surgical resection,” Dhillon said in a statement. “Thus, this patent will act as a part of the company’s core strategy as we continue to develop and build our commercialization strategy in China, one of the largest emerging oncology markets.”
OncoSec says cancer mortality has been increasing rapidly and continuously in China during the past three decades, citing studies that indicate 25 percent of all deaths in urban areas and 21 percent of deaths in rural areas are attributable to cancer.
The company claims ImmunoPulse and NeoPulse represent a potential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from cancer treatments such as surgery, systemic chemotherapy or immunotherapy.